Here are relevant reports on : recombinant-albumin-market
-
Global Albumin Market, by Product (Human Serum Albumin, Bovine Albumin, Recombinant Serum Albumin) by Application (Therapeutic, Drug Delivery, Culture Media, Vaccine Ingredient) by Region - Forecast to 2022
The global albumin market is projected to grow at a CAGR of around 6% during the forecast period (2017-2022). Factors such as the high demand of albumin in R&D activities, rising non-therapeutic application of albumin, development of plant based albumin, rising production of immunoglobulins, and rise in plasma collection are driving the market. However, the stringent regulations, limited reimbursement, and irrational uses and adverse effects associated with albumin are the factors restraining the growth of this market.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Albumin & Creatinine Tests Market by Product (Analyzers, Cartridges (PoC, Tabletop), Dipsticks, Kits, Reagents), Type (Blood & Urine Creatinine, Urine Albumin, Glycated Albumin), Enduser (Hospital, Diagnostic & Research Labs) - Global Forecast to 2025
The global albumin & creatinine tests market growth is primed to transition from $987 million in 2020 to $2,103 million by 2025, showcasing a strong CAGR of 16.3%. The growth of this market is driven by the growing prevalence of kidney disorders and diseases, the rising adoption of POC diagnostics, and the increasing prevalence of chronic conditions.
- Published: January 2021
- Price: $ 4950
- TOC Available:
-
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) - Global Forecast to 2028
The global plasma fractionation market, valued at US$27.2 billion in 2022, stood at US$29.0 billion in 2023 and is projected to advance at a resilient CAGR of 6.9% from 2025 to 2028, culminating in a forecasted valuation of US$40.4 billion by the end of the period. Market growth is driven mainly by factors such as the growing use of immunoglobulins in various therapeutic areas, strategic expansion of plasma collection centers/inventories by market players, and the growing prevalence of respiratory diseases and AATD
- Published: September 2023
- Price: $ 4950
- TOC Available:
-
Hemophilia Treatment Market by Indication (Type A, Type B), Therapy (Replacement (Recombinant, Plasma Derived), Route of Administration, End User - Global Forecast to 2027
The global hemophilia treatment market is projected to reach USD ~15 billion by 2027 from USD 12 Billion in 2022, at a CAGR of 5% during the forecast period. The major players in the global hemophilia market are Bayer Healthcare (Germany), Octapharma AG (Switzerland), Novo Nordisk (Denmark), Kedrion (Italy), Pfizer Inc. (US), Biogen (US) among others.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) - Global Forecasts to 2023
The global viral clearance market is projected to reach USD 724.5 million by 2023, growing at a CAGR of 21.7%. The key players in the global viral clearance market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France), Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).
- Published: September 2018
- Price: $ 4950
- TOC Available:
-
Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, vWD), Drug Class (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antibrinolytics, Fibrin Sealant) - Global Forecast to 2021
The global bleeding disorders treatment market size is projected to grow at a CAGR of 7.9%. The major factors driving the market growth include the growing patient population base, R&D activities, and increasing focus on recombinant products by pharmaceutical companies. Emerging markets offer significant growth opportunities for the bleeding disorders treatment market.
- Published: July 2016
- Price: $ 4950
- TOC Available:
-
Cancer Vaccines Market by Type (Preventive, Therapeutic (Neoantigen)), Technology (Cell-based Vaccine, Recombinant), Indication (Cervical, Prostate), ROA (Intramuscular, Intravenous), End User (Hospitals, Speciality Clinics) - Global Forecast to 2032
The global cancer vaccines market, valued at US$9.70 billion in 2023, stood at US$9.84 billion in 2024 and is projected to advance at a resilient CAGR of 5.4% from 2024 to 2032, culminating in a forecasted valuation of US$15.00 billion by the end of the period. The cancer vaccines market is growing rapidly, fueled by rising prevalence of cancer, technological advancements in immunotherapy, and increasing adoption of preventive healthcare across the globe.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028
The global recombinant proteins market, valued at US$2.1 billion in 2022, stood at US$2.2 billion in 2023 and is projected to advance at a resilient CAGR of 7.2% from 2023 to 2028, culminating in a forecasted valuation of US$3.2 billion by the end of the period. Growth in the market can be attributed to factors such as rising incidence of chronic diseases, growing demand for biologics and biosimilars due to expiration of patents, rising demand for customized medicine and increasing government initiatives for R&D in life sciences research.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral)-Global Forecast to 2030
The global vaccines market, valued at US$59.52 billion in 2024, stood at US$50.46 billion in 2025 and is projected to advance at a resilient CAGR of 4.8% from 2025 to 2030, culminating in a forecasted valuation of US$63.66 billion by the end of the period.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Bovine Serum Albumin Market by Form (Dry, Liquid), Grade (Technical-& Diagnostic-Grade, Research/Reagent-Grade, Food Grade), End User (Life Sciences Industry, Feed Industry, Food Industry, Research Institutes), and Region - Global Forecast to 2025
The Bovine Serum Albumin Market is expected to grow from USD 255 million in 2019 to USD 304 million by 2025, at a CAGR of 3.0% during the forecast period. This report includes a study on the marketing and development strategies, along with a study on the product portfolios of the leading companies operating in the bovine serum albumin market. It includes the profiles of leading companies such as Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc (US), Merck KGAA (Germany), Itoham Yonekyu Holdings Inc (Japan), Proliant Biologicals (US), Kraeber & Co Gmbh (Germany), Rockland Immunochemicals Inc (US), Rocky mountain biologicals (US), BelHealth investment partners, LLC (US), Bio-Techne Corporation (US), Prospec-Tany Technogene Ltd (Israel), LGC Group (UK), Promega Corporation (US), Biological Industries (Israel), and Serion GmbH (Germany).
- Published: August 2019
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
